Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 8/20 | 0.51 |
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | IL2 | P60568 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324491 | 1.00 | FPR2 (0.55) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL908205 | 0.86 | ACE (0.63) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL908204 | 0.86 | ACE (0.63) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL8726475 | 0.86 | ACE (0.63) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL11459400 | 0.86 | ACE (0.63) | NPSR1ACEMMEACE2CPA1 | |
| SCHEMBL11459401 | 0.86 | ACE (0.63) | NPSR1ACEMMEACE2CPA1 | |
| SCHEMBL5180354 | 0.86 | NPSR1 (0.69) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL8613833 | 0.86 | NPSR1 (0.69) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL5180357 | 0.86 | NPSR1 (0.69) | FPR2NPSR1ACEMMEACE2 | |
| SCHEMBL2099396 | 0.81 | NPSR1 (0.56) | FPR2NPSR1ACEMMEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20050159346-A1 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | VIP, IAPP, NGLY1 | FPR2 1498/4885NPSR1 1932/4885ACE 4078/4885 |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | FPR2 1498/4885NPSR1 1932/4885ACE 4078/4885 |
| US-20050159346-A1 | Cyclic peptide antitumor agents | VIP, IAPP, NGLY1 | FPR2 1498/4885NPSR1 1932/4885ACE 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.